SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stem Cell Research

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: midastouch017 who wrote (64)12/13/2004 7:52:36 PM
From: keokalani'nui   of 495
 
Schwarzenegger nominates stem cell research chief
Mon Dec 13, 2004 05:34 PM ET
By Leonard Anderson
SAN FRANCISCO, Dec 13 (Reuters) - California Gov. Arnold Schwarzenegger on Monday nominated a leading financial backer and campaigner for the state's stem cell initiative to chair a committee to oversee the $3 billion, 10-year research effort.

Schwarzenegger, a Republican, nominated Robert Klein, a real estate developer, for chairman and Edward Penhoet, co-founder and former chief executive officer of Chiron Corp. (CHIR.O: Quote, Profile, Research) , a pioneer of California's biotechnology industry, for vice chairman. Both are Democrats.

California Controller Steve Westly also selected the pair for the two top seats on the Independent Citizens Oversight Committee, a spokesman said.

Klein, who contributed about $2 million to the stem cell initiative and campaigned hard for its passage, is regarded as the leading contender for the post.

But some members of the oversight panel have called for a number of candidates to counter criticism that the public does not have enough say in the scientific program that will spend $300 million a year in state bond money for 10 years.

"I think there have to be choices. There has been no serious discussion of any other persons," said AIDS activist Jeff Sheehy, a committee appointee and spokesman for the UC-San Francisco AIDS Research Institute.

Klein was not available Monday, a spokeswoman said, but he issued a statement saying he pledged "to serve the interests of California citizens, its patients and taxpayers. ... I am committed to transparency in process, public oversight and accountability and the highest ethical and medical standards possible."

If elected chairman, Klein said he would "not hold any biomedical stock or investment interest during the term of office."

The committee, which will guide the work of the new California Institute for Regenerative Medicine, holds its first meeting on Friday in San Francisco.

Various state officials are appointing 27 members; the governor, lieutenant governor, controller and treasurer are nominating candidates for the two top positions, which will be voted on by the other committee members.

Some state lawmakers want to have more of a say in how the program is run and to make sure California reaps a return on the research.

Critics of the initiative have complained the research will benefit private biomedical companies and venture capitalists at the public's expense.

Democratic Sen. Deborah Ortiz, who supported the initiative and chairs the Senate Health Committee, has introduced a bill to protect the state's investment and bar conflicts of interest among private officials who will manage the research money.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext